Zobrazeno 1 - 10
of 3 783
pro vyhledávání: '"car t-cell therapy"'
Autor:
Alexandrina Balanean, Samuel Baird, Brooke Dulka, Luke Jennings‐Zhang, Robert N. Bone, Yolaine Jeune‐Smith, Bruce Feinberg, Muhamed Baljevic
Publikováno v:
eJHaem, Vol 5, Iss 6, Pp 1154-1164 (2024)
Abstract Introduction Initially approved for the fifth‐line or later therapeutic setting, the chimeric antigen receptor (CAR) T‐cell regimen ciltacabtagene autoleucel (cilta‐cel) was recently approved for second‐line (2L) treatment in relapse
Externí odkaz:
https://doaj.org/article/f96f1b2f20a343e0b5ab4238e1bad89f
Autor:
Maren Claus, Merle Freitag, Meike Ewald, Lea Rodon, Franca Deicher, Carsten Watzl, Philipp Kolb, Hanns-Martin Lorenz, Michael Schmitt, Wolfgang Merkt
Publikováno v:
Arthritis Research & Therapy, Vol 26, Iss 1, Pp 1-8 (2024)
Abstract Objective The high potential of CD19.CAR-T cells to treat autoimmune diseases such as Systemic Sclerosis (SSc) supposedly relies on the disappearance of autoantibodies. Here we investigated effects of CAR-T cells on the innate immune system
Externí odkaz:
https://doaj.org/article/36e1a80569564abc9a7e8ecb3eb2ee95
Autor:
Haiqiong Zheng, Houli Zhao, Shi Han, Delin Kong, Qiqi Zhang, Mingming Zhang, Yijin Chen, Meng Zhang, Yongxian Hu, He Huang
Publikováno v:
Experimental Hematology & Oncology, Vol 13, Iss 1, Pp 1-13 (2024)
Abstract Relapsed/refractory T cell-derived malignancies present with high heterogeneity and poor prognoses. Recently, chimeric antigen receptor (CAR)-T cell therapy has shown remarkable safety and efficacy in the treatment of B cell-derived malignan
Externí odkaz:
https://doaj.org/article/abc8c408c696440888885f5a945c4e91
Autor:
Yuhan Yan, Yixuan Tu, Qian Cheng, Jian Zhang, Erhua Wang, Zuqun Deng, Yan Yu, Liwen Wang, Rui Liu, Ling Chu, Liqing Kang, Jing Liu, Xin Li
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-13 (2024)
Abstract Background B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cell (CAR T-cell) therapy has exhibited remarkable efficacy in refractory or relapsed multiple myeloma (R/R MM), but recurrence and rapid progression of disease
Externí odkaz:
https://doaj.org/article/a60950bfb0a443be87c9a362b63aaf60
Autor:
David Mao, Anne S. Reiner, Xi Chen, Jae Park, Martina Pennisi, Miguel-Angel Perales, Edward K. Avila, Bianca D. Santomasso
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-9 (2024)
Abstract Patients who develop chimeric antigen receptor (CAR) T-cell-related immune effector cell-associated neurotoxicity syndrome (ICANS) frequently undergo evaluation with electroencephalography (EEG). We hypothesize that EEG features and Synek sc
Externí odkaz:
https://doaj.org/article/ec262d90bc1f4fecb5981ad4f7aba238
Publikováno v:
Experimental Hematology & Oncology, Vol 13, Iss 1, Pp 1-18 (2024)
Abstract Chimeric antigen receptor (CAR) T-cell therapy represents a highly efficacious treatment modality demonstrated to enhance outcomes in patients afflicted with malignancies, particularly those enduring relapsed or refractory hematological mali
Externí odkaz:
https://doaj.org/article/792ff3c390cb4a2e97d09c5b64d8c7d1
Autor:
Elisa Russo, Massimiliano Gambella, Anna Maria Raiola, Elena Beltrametti, Valentina Zanetti, Giuseppe Chirco, Francesca Viazzi, Emanuele Angelucci, Pasquale Esposito
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of hematologic malignancies, yet it carries significant risks, including acute kidney injury (AKI). In this study, we investigated the risk factors and clinica
Externí odkaz:
https://doaj.org/article/6f8a1ee9b08b477eb92a55a9a8bf549b
Autor:
Kexin Ai, Bowen Liu, Xiaomei Chen, Chuxin Huang, liping Yang, Weiya Zhang, Jianyu Weng, Xin Du, Kongming Wu, Peilong Lai
Publikováno v:
Journal of Hematology & Oncology, Vol 17, Iss 1, Pp 1-29 (2024)
Abstract Chimeric antigen receptor (CAR)-T cell therapy demonstrates substantial efficacy in various hematological malignancies. However, its application in solid tumors is still limited. Clinical studies report suboptimal outcomes such as reduced cy
Externí odkaz:
https://doaj.org/article/e9c3a324bf694c22927aea21e4a4bb88
Publikováno v:
Bezmiâlem Science, Vol 12, Iss 4, Pp 470-478 (2024)
Objective: Chimeric antigen receptor (CAR)-T cell therapy is a new immunotherapy approach that has started to been used in recent years and is developing rapidly. CAR-T cells, which are used as an immunotherapy treatment, destroy the tumor cell both
Externí odkaz:
https://doaj.org/article/315a3be6bc8a41409827051c74783e55
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-12 (2024)
Abstract Few studies evaluated patient-reported outcomes (PROs) for patients with hematologic malignancies receiving with Chimeric Antigen Receptor T (CAR-T) cell therapy. We performed a systematic review and meta-analysis to evaluate the benefits of
Externí odkaz:
https://doaj.org/article/d37c34b1d0d149ea9f410408e3c3ceb8